STAT3 and non-small cell lung carcinoma: Next, 30 minutes pre-treatment of NSCLC cells with a JAK inhibitor, Ruxolitinib at 10μM, as well as with a STAT3 inhibitor, STAT3 inhibitor VII at 10μM, significantly reduced the PGE2 effect (Figure 4B).